Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-R046 Monotherapy and in Combination With Tislelizumab in Advanced or Metastatic Solid Tumors
NCT06487858Phase 1Terminated
- Sponsor
- BeOne Medicines
- Start
- Jul 2024
- Primary completion
- Apr 2026
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BGB-R046 in solid tumor (3 arms), sponsored by BeOne Medicines. Primary endpoints: Number of Participant with Adverse Events, Serious Adverse Events, Adverse Events of Clinical Interest and Dose-limiting Toxicities, Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BGB-R046 and 2 more. Started Jul 2024; status: terminated.
02
Drugs
BGB-R046
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06487858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06487858.